Streetbeat News

Products Services

AAPL

QCOM

SSNLF

Apple Inc.'s iPhone 15 Pro, powered by the A17 Pro chipset, has outperformed Samsung Electronics Co Ltd.'s upcoming 2024 flagship, the Galaxy S24, in benchmark results by a 30% margin. The iPhone 15 Pro's single-core score stood at 2,914, while the unreleased Galaxy S24 Plus recorded 2,233 points. The Galaxy S24, powered by Qualcomm Inc.'s Snapdragon 8 Gen 3 chipset, also lagged behind in multi-core performance. Apple's superior performance has real-world implications, with AAA-rated desktop and console games like Death Stranding, Resident Evil 4, and the upcoming Ubisoft game Assassin's Creed Mirage able to run natively on the iPhone 15 Pro and iPhone 15 Pro Max.

Portfolio Pulse from Rounak Jain

September 14, 2023 | 11:33 am

AVXL

Anavex Life Sciences has announced a follow-on analysis of the Phase 2B/3 study of Blarcamesine (ANAVEX2-73) which demonstrated a statistically significant slowing in cognitive decline associated with Alzheimer's disease.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 11:32 am

VERO

Venus Concept has received a 510(K) clearance from the FDA to market its Venus Versa Pro System, a new multi-application platform for several aesthetic and cosmetic procedures.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 11:05 am

MBLY

Chinese automotive group, FAW Group, and autonomous driving solutions provider, Mobileye (NASDAQ:MBLY), have announced a strategic partnership. They will collaborate to create new products based on Mobileye's SuperVision and Chauffeur platforms.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 11:04 am

CSTL

Castle Biosciences' TissueCypher Barrett's Esophagus Test has outperformed the standard of care in risk-stratifying patients with Barrett's Esophagus. This could potentially lead to increased adoption of the test and boost the company's revenues.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 11:03 am

BHVN

Biohaven Ltd. (NYSE:BHVN) has completed enrollment for its Phase 3 pivotal study of taldefgrobep alfa in spinal muscular atrophy (SMA). The study, named RESILIENT, is a significant step in the development and commercialization of therapies for rare and common diseases.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 11:03 am

V

Paysend and Visa have announced a five-year strategic collaboration aimed at revolutionizing international money transfers through Visa Direct. The partnership will leverage Visa's global reach to expand Paysend's capabilities.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 11:03 am

VINC

Vincerx Pharma has begun dosing the first patient in a Phase 1 trial of VIP943 for relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia. Preliminary safety and pharmacology data is expected in 2024.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 11:02 am

TNXP

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced a poster presentation at the Seventh International Cancer Immunotherapy Conference 2023. The presentation involves TNX-1700 in preclinical colorectal cancer models. The conference will be held in Milan, Italy, from September 20-23, 2023.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 11:02 am